Tomohide Tamura

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2003 · 2.9K citations

Medicine, Oncology, Pharmacology +13

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine · 2002 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Toshimi Takano, Yuichiro Ohe, Hiromi Sakamoto et al. · Journal of Clinical Oncology · 2005 · 708 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

Minoru Takada, Masahiro Fukuoka, Masaaki Kawahara et al. · Journal of Clinical Oncology · 2002 · 704 citations

Medicine, Oncology, Radiation Oncology +14